JP2012523430A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523430A5
JP2012523430A5 JP2012504880A JP2012504880A JP2012523430A5 JP 2012523430 A5 JP2012523430 A5 JP 2012523430A5 JP 2012504880 A JP2012504880 A JP 2012504880A JP 2012504880 A JP2012504880 A JP 2012504880A JP 2012523430 A5 JP2012523430 A5 JP 2012523430A5
Authority
JP
Japan
Prior art keywords
degenerative disorder
piperzine
diol
prodrug
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012504880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523430A (ja
JP5634498B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/030470 external-priority patent/WO2010118282A1/en
Publication of JP2012523430A publication Critical patent/JP2012523430A/ja
Publication of JP2012523430A5 publication Critical patent/JP2012523430A5/ja
Application granted granted Critical
Publication of JP5634498B2 publication Critical patent/JP5634498B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012504880A 2009-04-09 2010-04-09 中枢神経系の変性障害の予防および/または治療方法 Active JP5634498B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16810109P 2009-04-09 2009-04-09
US61/168,101 2009-04-09
PCT/US2010/030470 WO2010118282A1 (en) 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system

Publications (3)

Publication Number Publication Date
JP2012523430A JP2012523430A (ja) 2012-10-04
JP2012523430A5 true JP2012523430A5 (enExample) 2013-05-16
JP5634498B2 JP5634498B2 (ja) 2014-12-03

Family

ID=42934882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012504880A Active JP5634498B2 (ja) 2009-04-09 2010-04-09 中枢神経系の変性障害の予防および/または治療方法

Country Status (11)

Country Link
US (1) US8304429B2 (enExample)
EP (1) EP2416655B1 (enExample)
JP (1) JP5634498B2 (enExample)
CN (1) CN102448306B (enExample)
AU (1) AU2010233187B2 (enExample)
BR (1) BRPI1015472A2 (enExample)
CA (1) CA2758187C (enExample)
ES (1) ES2505243T3 (enExample)
IL (1) IL215584A (enExample)
NZ (1) NZ595630A (enExample)
WO (1) WO2010118282A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5645918B2 (ja) * 2009-04-09 2014-12-24 アミカス セラピューティックス インコーポレイテッド リソソーム蓄積障害の予防および/または治療方法
RU2015147509A (ru) * 2009-10-19 2019-01-14 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
WO2011049737A1 (en) 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
EP3521451A1 (en) 2010-11-17 2019-08-07 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
WO2013070981A2 (en) * 2011-11-08 2013-05-16 University Of Central Florida Research Foundation, Inc. Treating er stress related disorders by stabilizing intracellular calcium homeostasis
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
JP2017502961A (ja) 2013-12-23 2017-01-26 アレクトス セラピューティックス インコーポレイテッド グルコセレブロシダーゼモジュレーターおよびその使用
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
EP3509639A1 (en) * 2016-09-12 2019-07-17 Steven Hoffman Compositions for treating dementia
RU2019114679A (ru) 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
MY203356A (en) 2018-01-12 2024-06-25 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019140236A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN119606967B (zh) * 2024-12-13 2025-09-05 合肥工业大学 氯雷他定在制备用于预防和治疗血管钙化药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1890295A (en) * 1994-03-09 1995-09-25 Novo Nordisk A/S Piperidines and pyrrolidines
WO2002076440A2 (en) * 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6670625B1 (en) * 2002-06-18 2003-12-30 Ge Medical Systems Global Technology Company, Llc Method and apparatus for correcting multipole aberrations of an electron beam in an EBT scanner
JP2006507359A (ja) * 2002-10-28 2006-03-02 ノボ・ノルデイスク・エー/エス 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用
ES2485369T3 (es) * 2005-06-08 2014-08-13 Amicus Therapeutics, Inc. Tratamiento de trastornos del SNC asociados con mutaciones en genes que codifican enzimas lisosómicas
DK2040548T3 (da) * 2006-06-23 2012-08-13 Amicus Therapeutics Inc Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase
US20080009156A1 (en) 2006-07-10 2008-01-10 Malin Glen K System and method for bonding coaxial cable
JP5645918B2 (ja) * 2009-04-09 2014-12-24 アミカス セラピューティックス インコーポレイテッド リソソーム蓄積障害の予防および/または治療方法

Similar Documents

Publication Publication Date Title
JP2018518537A5 (enExample)
JP2012523431A5 (enExample)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2010510202A5 (enExample)
JP2016513734A5 (enExample)
JP2013525444A5 (enExample)
FI2291080T5 (fi) Uusia sfingosiinifosfaattireseptorimodulaattoreita
HRP20151443T1 (hr) Terapijsko sredstvo protiv stenoze kralježniäśnog kanala
MX356032B (es) Compuestos indola y métodos para tratar el dolor visceral.
RU2018103338A (ru) Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
JP2018516992A5 (enExample)
JP2013522230A5 (enExample)
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
JP2015523407A5 (enExample)
WO2008119057A3 (en) The use of pde7 inhibitors for the treatment of movement disorders
JP2015500257A5 (enExample)
NZ595630A (en) Methods for preventing and/or treating degenerative disorders of the central nervous system
JP2010518061A5 (enExample)
JP2018507886A5 (enExample)
NZ595629A (en) Methods for preventing and/or treating lysosomal storage disorders
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2013516488A (ja) 炭酸脱水酵素阻害薬およびさらなる活性剤の組み合わせによる閉塞型睡眠時無呼吸症候群の治療
SI2419104T1 (en) Combinations of 5-HT4 receptor agonists and acetylcholinesterase inhibitors for the treatment of cognitive disorders
JP2015510916A5 (enExample)
JP2015520221A5 (enExample)